ReviewAnnals of the rheumatic diseases1999
Etanercept: therapeutic use in patients with rheumatoid arthritis.
Review in Annals of the rheumatic diseases, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 105 citations in OpenAlex.
- Comparison of the Pharmacokinetics, Safety, and Tolerability of the Autoinjector (AI) and Pre-Filled Syringe (PFS) of SB4 in Healthy Subjects.Drug design, development and therapy · 2020Trial
- PD-1MedComm · 2026Article
- Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- The role of inflammation in autoimmune disease: a therapeutic target.Frontiers in immunology · 2023Review
- Etanercept embedded silk fibroin/pullulan hydrogel enhance cartilage repair in bone marrow stimulation.Frontiers in bioengineering and biotechnology · 2022Article
- sTNFRII-Fc modification protects human UC-MSCs against apoptosis/autophagy induced by TNF-α and enhances their efficacy in alleviating inflammatory arthritis.Stem cell research & therapy · 2021Article
- Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients.Medicine · 2020Observational
- A paradigm shift in studies based on rheumatoid arthritis clinical registries.The Korean journal of internal medicine · 2019Review
- The Neonatal Fc Receptor (FcRn): A Misnomer?Frontiers in immunology · 2019Review
- Role of Interstitial Fluid Turnover on Target Suppression by Therapeutic Biologics Using a Minimal Physiologically Based Pharmacokinetic Model.The Journal of pharmacology and experimental therapeutics · 2018Article
- Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study.Therapeutics and clinical risk management · 2018Article
- Review
- Article
- Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis.Journal of multidisciplinary healthcare · 2013Article
- Placenta suppresses experimental autoimmune hypophysitis through soluble TNF receptor 1.Journal of autoimmunity · 2012Article
- Etanercept in the treatment of rheumatoid arthritis: clinical follow-up over one year by ultrasonography.Clinical rheumatology · 2008Article
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.Annals of the rheumatic diseases · 2007Review
- The safety of etanercept for the treatment of plaque psoriasis.Therapeutics and clinical risk management · 2007Article
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.Annals of the rheumatic diseases · 2006Article
- Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.Annals of the rheumatic diseases · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumour necrosis factor (TNF) plays a central part in the pathophysiology of rheumatoid arthritis (RA). TNF initiates signal transduction by interacting with surface bound TNF receptors. Soluble tumour necrosis factor receptors (sTNFRs) act as natural inhibitors of TNF activity. Etanercept, recombinant p75 sTNFR:Fc fusion protein, has received approval from the US Food and Drug Administration for patients with RA and juvenile RA (JRA) who have failed treatment with at least one other drug. Etanercept has demonstrated excellent safety and efficacy in large scale, randomised, double blind, placebo controlled trials of patients with RA and JRA who are refractory to other disease modifying anti-rheumatic drugs. The therapeutic effects mediated by etanercept are rapid and sustained. Combining etanercept with methotrexate was found to be safe and more effective than treatment with methotrexate alone in the treatment of RA. These clinical findings demonstrate that etanercept can result in symptomatic improvement in patients with RA and JRA. Etanercept is an important new addition to the treatment of these diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.